Epstein Secrets

eam, Poxvirus and Rabies Branch, Division of High Conseque=ce Pathogens and Pathology, National Center of Emerging Zoonotic a=d Infectious Diseases, Centers for Disease Control and Prevention,&nbs=;Atlanta, GA 6. Department of Pathology and Laboratory Medicine, Weill Medical Colle=e of Cornell University, New York, NY 7. D

evices suitable f=r working in developing countries, and may be powered and run by a cell phone or smart device. • Current CDC approved EZ1-RT-P=R Taqman assay has LOD of 5,000 PFU/ml. This works when patient is&nbs=;febrile, i.e. has overt symptoms and may be contagious. • Next level of assay needs

eam, Poxvirus and Rabies Branch, Division of High Consequ=nce Pathogens and Pathology, National Center of Emerging Zoonoti= and Infectious Diseases, Centers for Disease Control and Prevention,*Atlanta, GA 6. Department of Pathology and Laboratory Medicine, Weill Medical Coll=ge of Cornell University, New York, NY 7. Depa

ricated devices that w=ll allow for electronic detection, obviating the need for expens=ve hardware used in most fluorescent detection schemes (i.e. Taqman a=says). As such, we are poised to combine these technologie= for rapidly identifying and providing quantitative viral load fo= all the VHF, Variol

eam, Poxvirus and Rabies Branch, Division of High Conseque=ce Pathogens and Pathology, National Center of Emerging Zoonotic a=d Infectious Diseases, Centers for Disease Control and Prevention,&nbs=;Atlanta, GA 6. Department of Pathology and Laboratory Medicine, Weill Medical Colle=e of Cornell University, New York, NY 7.

devices suitable f=r working in developing countries, and may be powered and run by a cell phone or smart device. • Current CDC approved EZ1-RT-P=R Taqman assay has LOD of 5,000 PFU/ml. This works when patient is&nbs=;febrile, i.e. has overt symptoms and may be contagious. • Next level of assay needs